The first-ever cancer clinic on an American Indian reservation may close–unless CMS changes payment rules

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.

May 01, 2026

Vol.52 No.17

Cancer Policy

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

The Centers for Medicare and Medicaid Services and FDA announced a new coverage pathway—called the Regulatory Alignment for Predictable and Immediate Device, or RAPID pathway—designed to expedite access to certain FDA-designated Class II and Class III Breakthrough devices for people with Medicare.

April 24, 2026

Vol.52 No.16

Cancer Policy

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

The Centers for Medicare & Medicaid Services issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule, which aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior authorization, or ePA, requirements for covered prescription drugs and expedite federal response deadlines to ensure patients receive life-critical medications without administrative delay.

CMS proposes rule to update Medicare payments and transparency requirements for hospice care

The Centers for Medicare & Medicaid Services has proposed a rule to update Medicare payments for hospice care in the next fiscal year, which begins on Oct. 1.

PanTracer LBx liquid biopsy profiling test receives Medicare coverage

NeoGenomics announced the PanTracer LBx test has received coverage from CMS’ Molecular Diagnostics Services Program under Local Coverage Determination - MolDX: Plasma-Based Genomic Profiling in Solid Tumors.

March 20, 2026

Vol.52 No.11

Cancer Policy

CMS to enter negotiations with drugmakers over the price of four cancer medications

The Center for Medicare and Medicaid Services is entering negotiations with drugmakers over the price of 15 medications this year. The newly announced list includes four drugs used to treat cancer.

January 30, 2026

Vol.52 No.04

By Sara Willa Ernst

The first-ever cancer clinic on an American Indian reservation may close–unless CMS changes payment rules

YOU MAY BE INTERESTED IN

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

CMS proposes rule to update Medicare payments and transparency requirements for hospice care

PanTracer LBx liquid biopsy profiling test receives Medicare coverage

CMS to enter negotiations with drugmakers over the price of four cancer medications

Renew today!

Subscriber content

Never miss an issue!

Login